Bardoxolone methyl treatment resulted in significant weight loss in a generally obese patient population with T2DM and stage 4 CKD, with the magnitude and rate dependent on baseline BMI.
- Bardoxolone methyl treatment resulted in significant reductions in body weight in a generally overweight patient population with T2DM and stage 4 CKD.
- The magnitude and rate of weight reductions were more pronounced in patients with higher baseline BMI. The loss in body weight was accompanied by a significant reduction in waist circumference, with declines proportional to both baseline body weight and BMI.
- In a subset of patients who provided timed urine collections, there was no reduction in 24-hour urinary creatinine excretion, suggesting that bardoxolone methyl does not adversely affect creatinine production and serum creatinine-based eGFR is therefore an appropriate measure of kidney function in response to bardoxolone methyl treatment.